search

Active clinical trials for "Multiple Myeloma"

Results 91-100 of 3165

CD 70 CAR T for Patients With CD70 Positive Malignant Hematologic Diseases

Acute Myeloid LeukemiaNon-hodgkin's Lymphoma1 more

A Study of CD 70 CAR T for patients with CD70 positive malignant hematologic diseases

Recruiting49 enrollment criteria

NXC-201 (Formerly HBI0101) Multiple Myeloma

Dose Escalation and Safety

It is a phase one study with dose escalation and safety CART in BCMA- Expressing Multiple Myeloma and AL amyloidosis Patients

Recruiting14 enrollment criteria

Selinexor With Alternating Bortezomib or Lenalidomide Plus Dexamethasone in TIE Newly Diagnosed...

Multiple Myeloma

An unrandomized phase 2 study of selinexor in combination with lenalidomide/ bortezomib and dexamethasone to newly diagnosed, transplant in-eligible symptomatic multiple myeloma patients in a multicenter international set-up within the Nordic Multiple Myeloma Study Group

Recruiting35 enrollment criteria

Targeting CD19 and BCMA CAR-T Cells Immunotherapy in Patients With Relapsed or Refractory Multiple...

Multiple Myeloma

Evaluation the safety,tolerability, preliminary efficacy,and PK/PD of CD19-BCMA CAR-T cells for the treatment of multiple myeloma

Recruiting18 enrollment criteria

Study to Assess the Safety and Tolerability of CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma...

Multiple MyelomaLymphoma1 more

The purpose of this study is to characterize the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity of CFT7455 administered orally in subjects with Relapsed/Refractory (r/r) Non-Hodgkin's Lymphoma (NHL) or Multiple Myeloma (MM) administered according to different dosing schedules as a single agent and in combination with dexamethasone.

Recruiting46 enrollment criteria

Bortezomib, Isatuximab, Cyclophosphamide and Dexamethasone Induction in Transplant-Eligible Multiple...

Multiple Myeloma

This is a single-arm, open-label phase II study with a safety lead-in phase.

Recruiting60 enrollment criteria

A Multicentre, Non-Blinded Study Exploring Self-Administration of Chemotherapy in the Home Environment...

MyelomaMyeloma Multiple

This study is to see if the standard of care subcutaneous injection of bortezomib can safely be administered at home by the patient or caregiver. All tests and assessments are based on standard of care procedures.

Recruiting12 enrollment criteria

Double Filtration Plasmapheresis Combined With Chemotherapy

Multiple Myeloma

Evaluation of double filtration plasmapheresis combined with chemotherapy for the treatment of abnormalities of M protein or renal function due to the multiple myeloma.

Recruiting19 enrollment criteria

Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma...

Multiple Myeloma

This is a multicenter, open-label phase II study in subjects with relapsed and/or refractory multiple myeloma with at least two prior lines of therapy. The main study consists of three phases: a 28-day screening phase, treatment phase that consists of 28-day cycles of isatuximab with elotuzumab, pomalidomide, and dexamethasone and a follow-up phase.

Recruiting55 enrollment criteria

DARA RVD For High Risk SMM

High-risk Smoldering Multiple MyelomaMultiple Myeloma

The purpose of this research study is to learn whether the combination of daratumumab SC ( Darzalex Faspro), lenalidomide (Revlimid), bortezomib (Velcade) and dexamethasone works in treating smoldering multiple myeloma and preventing progression to active or symptomatic multiple myeloma. The names of the study drugs involved in this study are: Daratumumab (also called Darzalex Faspro) Bortezomib (also called Velcade) Lenalidomide (also called Revlimid) Dexamethasone

Recruiting55 enrollment criteria
1...91011...317

Need Help? Contact our team!


We'll reach out to this number within 24 hrs